Skip to main content
Top
Published in: Journal of Nephrology 3/2018

01-06-2018 | Review

Pathology and diagnosis of renal non-AL amyloidosis

Authors: Sanjeev Sethi, Jason D. Theis

Published in: Journal of Nephrology | Issue 3/2018

Login to get access

Abstract

Renal amyloidosis is characterized by acellular Congo red positive deposits in the glomeruli, interstitium and/or arteries. Light chain restriction on immunofluorescence studies is present in AL-amyloidosis, the most common type of amyloidosis involving the kidney. The detection of Congo red positive deposits coupled with negative immunofluorescence studies is highly suggestive of non-AL amyloidosis. Some of the non-AL amyloidosis are common while others are relatively rare. The clinical features, laboratory and renal pathology findings are helpful in the diagnosis and typing of non-AL amyloidosis. Thus, ALECT2 amyloidosis is characterized by diffuse cortical interstitial amyloid deposits, AA amyloidosis shows vascular deposits in addition to the glomerular deposits, AFib amyloidosis is characterized by massive amyloid accumulation limited to the glomeruli resulting in the obliteration of glomerular architecture, AApoA1 and AApoAIV are characterized by large amyloid deposits restricted to the medulla, and AGel shows swirling patterns of amyloid fibrils on electron microscopy. While light microscopy is very helpful, accurate typing of non-AL amyloidosis then requires immunohistochemical or laser microdissection/mass spectrometry studies of the Congo red positive deposits. Immunohistochemical studies are available for some of the non-AL amyloidosis. On the other hand, mass spectrometry analysis is a one stop methodology for confirmation and typing of amyloidosis. The diagnosis and typing of amyloidosis by mass spectrometry is based on finding the signature amyloid peptides, apolipoprotein E and serum amyloid-P component, followed by detection of precursor amyloidogenic protein such as LECT2, fibrinogen-α, gelsolin, etc. To, summarize, non-AL amyloidosis is a group of amyloidosis with distinctive clinical, laboratory and renal pathology findings. Typing of the amyloidosis is best performed using mass spectrometry methodology. Accurate typing of non-AL amyloidosis is imperative for correct management, prognosis, and genetic counseling.
Literature
2.
3.
go back to reference Said SM, Sethi S, Valeri AM et al (2013) Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol 8:1515–1523CrossRefPubMedPubMedCentral Said SM, Sethi S, Valeri AM et al (2013) Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol 8:1515–1523CrossRefPubMedPubMedCentral
4.
go back to reference Sethi S, Theis JD, Leung N et al (2010) Mass spectrometry based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. Clin J Am Soc Nephrol 5:2180–2187CrossRefPubMedPubMedCentral Sethi S, Theis JD, Leung N et al (2010) Mass spectrometry based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. Clin J Am Soc Nephrol 5:2180–2187CrossRefPubMedPubMedCentral
5.
go back to reference Picken MM (2007) New insights into systemic amyloidosis: the importance of diagnosis of specific type. Curr Opin Nephrol Hypertens 16:196–203CrossRefPubMed Picken MM (2007) New insights into systemic amyloidosis: the importance of diagnosis of specific type. Curr Opin Nephrol Hypertens 16:196–203CrossRefPubMed
6.
go back to reference Vigushin DM, Gough J, Allan D et al (1994) Familial nephropathic systemic amyloidosis caused by apolipoprotein Al variant Arg26. QJM 87:149–154PubMed Vigushin DM, Gough J, Allan D et al (1994) Familial nephropathic systemic amyloidosis caused by apolipoprotein Al variant Arg26. QJM 87:149–154PubMed
7.
go back to reference Yazaki M, Liepnieks JJ, Barats MS, Cohen AH, Benson MD (2003) Hereditary systemic amyloidosis associated with a new apolipoprotein AII stop codon mutation Stop78Arg. Kidney Int 64:11–16CrossRefPubMed Yazaki M, Liepnieks JJ, Barats MS, Cohen AH, Benson MD (2003) Hereditary systemic amyloidosis associated with a new apolipoprotein AII stop codon mutation Stop78Arg. Kidney Int 64:11–16CrossRefPubMed
8.
go back to reference Yazaki M, Liepnieks JJ, Yamashita T, Guenther B, Skinner M, Benson MD (2001) Renal amyloidosis caused by a novel stop-codon mutation in the apolipoprotein A-II gene. Kidney Int 60:1658–1665CrossRefPubMed Yazaki M, Liepnieks JJ, Yamashita T, Guenther B, Skinner M, Benson MD (2001) Renal amyloidosis caused by a novel stop-codon mutation in the apolipoprotein A-II gene. Kidney Int 60:1658–1665CrossRefPubMed
9.
go back to reference Benson M JL, Uemichi T, Wheeler G, Correa R (1993) Hereditary renal amyloidosis associated with a mutant fibrinogen [alpha]-chain. Blood 3:252–255 Benson M JL, Uemichi T, Wheeler G, Correa R (1993) Hereditary renal amyloidosis associated with a mutant fibrinogen [alpha]-chain. Blood 3:252–255
10.
go back to reference Benson MD (2005) Ostertag revisited: the inherited systemic amyloidoses without neuropathy. Amyloid 12:75–87CrossRefPubMed Benson MD (2005) Ostertag revisited: the inherited systemic amyloidoses without neuropathy. Amyloid 12:75–87CrossRefPubMed
11.
go back to reference Joy T, Wang J, Hahn A, Hegele RA (2003) Apoa1 related amyloidosis: a case report and literature review. Clin Biochem 36:641–645CrossRefPubMed Joy T, Wang J, Hahn A, Hegele RA (2003) Apoa1 related amyloidosis: a case report and literature review. Clin Biochem 36:641–645CrossRefPubMed
12.
go back to reference Gillmore JD, Booth DR, Madhoo S, Pepys MB, Hawkins PN (1999) Hereditary renal amyloidosis associated with variant lysozyme in a large English family. Nephrol Dial Transplant 14:2639–2644CrossRefPubMed Gillmore JD, Booth DR, Madhoo S, Pepys MB, Hawkins PN (1999) Hereditary renal amyloidosis associated with variant lysozyme in a large English family. Nephrol Dial Transplant 14:2639–2644CrossRefPubMed
13.
go back to reference Dasari S, Amin MS, Kurtin PJ et al. Clinical, biopsy, and mass spectrometry characteristics of renal apolipoprotein A-IV amyloidosis. Kidney International;90:658–664 Dasari S, Amin MS, Kurtin PJ et al. Clinical, biopsy, and mass spectrometry characteristics of renal apolipoprotein A-IV amyloidosis. Kidney International;90:658–664
14.
go back to reference Sethi S, Dasari S, Amin MS et al (2017) Clinical, biopsy, and mass spectrometry findings of renal gelsolin amyloidosis. Kidney Int 91:964–971CrossRefPubMed Sethi S, Dasari S, Amin MS et al (2017) Clinical, biopsy, and mass spectrometry findings of renal gelsolin amyloidosis. Kidney Int 91:964–971CrossRefPubMed
15.
go back to reference Lachmann HJ, Goodman HJB, Gilbertson JA et al (2007) Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356:2361–2371CrossRefPubMed Lachmann HJ, Goodman HJB, Gilbertson JA et al (2007) Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356:2361–2371CrossRefPubMed
17.
go back to reference Verine J, Mourad N, Desseaux K et al (2007) Clinical and histological characteristics of renal AA amyloidosis: a retrospective study of 68 cases with a special interest to amyloid-associated inflammatory response. Hum Pathol 38:1798–1809CrossRefPubMed Verine J, Mourad N, Desseaux K et al (2007) Clinical and histological characteristics of renal AA amyloidosis: a retrospective study of 68 cases with a special interest to amyloid-associated inflammatory response. Hum Pathol 38:1798–1809CrossRefPubMed
18.
go back to reference Saha A, Chopra Y, Theis JD, Vrana JA, Sethi S (2013) AA amyloidosis associated with systemic-onset juvenile idiopathic arthritis. Am J Kidney Dis 62:834–838CrossRefPubMed Saha A, Chopra Y, Theis JD, Vrana JA, Sethi S (2013) AA amyloidosis associated with systemic-onset juvenile idiopathic arthritis. Am J Kidney Dis 62:834–838CrossRefPubMed
19.
go back to reference Lane T, Loeffler JM, Rowczenio DM et al (2013) Brief report: AA amyloidosis complicating the hereditary periodic fever syndromes. Arthritis Rheum 65:1116–1121CrossRefPubMed Lane T, Loeffler JM, Rowczenio DM et al (2013) Brief report: AA amyloidosis complicating the hereditary periodic fever syndromes. Arthritis Rheum 65:1116–1121CrossRefPubMed
20.
go back to reference Benson MD, James S, Scott K, Liepnieks JJ, Kluve-Beckerman B (2008) Leukocyte chemotactic factor 2: A novel renal amyloid protein. Kidney Int 74:218–222CrossRefPubMed Benson MD, James S, Scott K, Liepnieks JJ, Kluve-Beckerman B (2008) Leukocyte chemotactic factor 2: A novel renal amyloid protein. Kidney Int 74:218–222CrossRefPubMed
21.
go back to reference Said SM, Sethi S, Valeri AM et al (2014) Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis. Kidney Int 86:370–377CrossRefPubMed Said SM, Sethi S, Valeri AM et al (2014) Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis. Kidney Int 86:370–377CrossRefPubMed
22.
go back to reference Nasr SH, Dogan A, Larsen CP (2015) Leukocyte cell–derived chemotaxin 2–associated amyloidosis: a recently recognized disease with distinct clinicopathologic characteristics. Clin J Am Soc Nephrol 10:2084–2093CrossRefPubMedPubMedCentral Nasr SH, Dogan A, Larsen CP (2015) Leukocyte cell–derived chemotaxin 2–associated amyloidosis: a recently recognized disease with distinct clinicopathologic characteristics. Clin J Am Soc Nephrol 10:2084–2093CrossRefPubMedPubMedCentral
23.
go back to reference Paueksakon P, Fogo AB, Sethi S (2014) Leukocyte chemotactic factor 2 amyloidosis cannot be reliably diagnosed by immunohistochemical staining. Hum Pathol 45:1445–1450CrossRefPubMed Paueksakon P, Fogo AB, Sethi S (2014) Leukocyte chemotactic factor 2 amyloidosis cannot be reliably diagnosed by immunohistochemical staining. Hum Pathol 45:1445–1450CrossRefPubMed
24.
go back to reference Gillmore JD, Lachmann HJ, Rowczenio D et al (2009) Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen Aα-chain amyloidosis. J Am Soc Nephrol 20:444–451CrossRefPubMedPubMedCentral Gillmore JD, Lachmann HJ, Rowczenio D et al (2009) Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen Aα-chain amyloidosis. J Am Soc Nephrol 20:444–451CrossRefPubMedPubMedCentral
26.
go back to reference Stangou AJ, Banner NR, Hendry BM et al (2010) Hereditary fibrinogen A α-chain amyloidosis: phenotypic characterization of a systemic disease and the role of liver transplantation. Blood 115:2998–3007CrossRefPubMed Stangou AJ, Banner NR, Hendry BM et al (2010) Hereditary fibrinogen A α-chain amyloidosis: phenotypic characterization of a systemic disease and the role of liver transplantation. Blood 115:2998–3007CrossRefPubMed
27.
go back to reference Gillmore JD, Booth DR, Rela M et al (2000) Curative hepatorenal transplantation in systemic amyloidosis caused by the Glu526Val fibrinogen {alpha}-chain variant in an English family. QJM 93:269–275CrossRefPubMed Gillmore JD, Booth DR, Rela M et al (2000) Curative hepatorenal transplantation in systemic amyloidosis caused by the Glu526Val fibrinogen {alpha}-chain variant in an English family. QJM 93:269–275CrossRefPubMed
28.
go back to reference Sethi S, Ters ME, Vootukuru S, Qian Q (2011) Recurrent AA amyloidosis in a kidney transplant. Am J Kidney Dis 57:941–944CrossRefPubMed Sethi S, Ters ME, Vootukuru S, Qian Q (2011) Recurrent AA amyloidosis in a kidney transplant. Am J Kidney Dis 57:941–944CrossRefPubMed
29.
go back to reference Meretoja J (1969) Familial systemic paramyloidosis with lattice dystrophy of the cornea, progressive cranial neuropathy, skin changes and various internal symptoms. A previously unrecognized heritable syndrome. Ann Clin Res 1:314–324PubMed Meretoja J (1969) Familial systemic paramyloidosis with lattice dystrophy of the cornea, progressive cranial neuropathy, skin changes and various internal symptoms. A previously unrecognized heritable syndrome. Ann Clin Res 1:314–324PubMed
30.
31.
go back to reference Maury CPJ, Kere J, Tolvanen R, de la Chapelle A (1990) Finnish hereditary amyloidosis is caused by a single nucleotide substitution in the gelsolin gene. FEBS Lett 276:75–77CrossRefPubMed Maury CPJ, Kere J, Tolvanen R, de la Chapelle A (1990) Finnish hereditary amyloidosis is caused by a single nucleotide substitution in the gelsolin gene. FEBS Lett 276:75–77CrossRefPubMed
32.
go back to reference Maury CPJ, Kere J, Tolvanen R, de la Chapelle A (1992) Homozygosity for the Asn187 gelsolin mutation in Finnish-type familial amyloidosis is associated with severe renal disease. Genomics 13:902–903CrossRefPubMed Maury CPJ, Kere J, Tolvanen R, de la Chapelle A (1992) Homozygosity for the Asn187 gelsolin mutation in Finnish-type familial amyloidosis is associated with severe renal disease. Genomics 13:902–903CrossRefPubMed
33.
go back to reference Sethi S, Theis JD, Quint P et al (2013) Renal Amyloidosis Associated With a Novel Sequence Variant of Gelsolin. Am J Kidney Dis 61:161–166CrossRefPubMed Sethi S, Theis JD, Quint P et al (2013) Renal Amyloidosis Associated With a Novel Sequence Variant of Gelsolin. Am J Kidney Dis 61:161–166CrossRefPubMed
34.
go back to reference Gregorini G, Izzi C, Ravani P et al (2015) Tubulointerstitial nephritis is a dominant feature of hereditary apolipoprotein A-I amyloidosis. Kidney Int 87:1223–1229CrossRefPubMed Gregorini G, Izzi C, Ravani P et al (2015) Tubulointerstitial nephritis is a dominant feature of hereditary apolipoprotein A-I amyloidosis. Kidney Int 87:1223–1229CrossRefPubMed
35.
go back to reference Rowczenio D, Dogan A, Theis JD et al (2011) Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. Am J Pathol 179:1978–1987CrossRefPubMedPubMedCentral Rowczenio D, Dogan A, Theis JD et al (2011) Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. Am J Pathol 179:1978–1987CrossRefPubMedPubMedCentral
36.
go back to reference Gregorini G, Izzi C, Obici L et al (2005) Renal apolipoprotein a-i amyloidosis: a rare and usually ignored cause of hereditary tubulointerstitial nephritis. J Am Soc Nephrol 16:3680–3686CrossRefPubMed Gregorini G, Izzi C, Obici L et al (2005) Renal apolipoprotein a-i amyloidosis: a rare and usually ignored cause of hereditary tubulointerstitial nephritis. J Am Soc Nephrol 16:3680–3686CrossRefPubMed
37.
go back to reference Obici L, Palladini G, Giorgetti S et al (2004) Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families. Gastroenterology 126:1416–1422CrossRefPubMed Obici L, Palladini G, Giorgetti S et al (2004) Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families. Gastroenterology 126:1416–1422CrossRefPubMed
38.
go back to reference Traynor CA, Tighe D, O’Brien FJ et al (2013) Clinical and pathologic characteristics of hereditary apolipoprotein A-I amyloidosis in Ireland. Nephrology 18:549–554CrossRefPubMed Traynor CA, Tighe D, O’Brien FJ et al (2013) Clinical and pathologic characteristics of hereditary apolipoprotein A-I amyloidosis in Ireland. Nephrology 18:549–554CrossRefPubMed
39.
go back to reference Gillmore JD, Stangou AJ, Lachmann HJ et al (2006) Organ Transplantation in Hereditary Apolipoprotein AI Amyloidosis. Am J Transplant 6:2342–2347CrossRefPubMed Gillmore JD, Stangou AJ, Lachmann HJ et al (2006) Organ Transplantation in Hereditary Apolipoprotein AI Amyloidosis. Am J Transplant 6:2342–2347CrossRefPubMed
40.
go back to reference De Gracia R, Fernández EJ, Riñón C, Selgas R, Garcia-Bustos J (2006) Hereditary renal amyloidosis associated with a novel mutation in the apolipoprotein AII gene. QJM: An International. J Med 99:274- De Gracia R, Fernández EJ, Riñón C, Selgas R, Garcia-Bustos J (2006) Hereditary renal amyloidosis associated with a novel mutation in the apolipoprotein AII gene. QJM: An International. J Med 99:274-
41.
go back to reference Benson MD, Liepnieks JJ, Yazaki M et al (2001) A new human hereditary amyloidosis: the result of a stop-codon mutation in the apolipoprotein AII gene. Genomics 72:272–277CrossRefPubMed Benson MD, Liepnieks JJ, Yazaki M et al (2001) A new human hereditary amyloidosis: the result of a stop-codon mutation in the apolipoprotein AII gene. Genomics 72:272–277CrossRefPubMed
42.
go back to reference Sethi S, Theis JD, Shiller SM et al (2012) Medullary amyloidosis associated with apolipoprotein A-IV deposition. Kidney Int 81:201–206CrossRefPubMed Sethi S, Theis JD, Shiller SM et al (2012) Medullary amyloidosis associated with apolipoprotein A-IV deposition. Kidney Int 81:201–206CrossRefPubMed
43.
go back to reference Nasr SH, Dasari S, Hasadsri L et al (2017) Novel type of renal amyloidosis derived from apolipoprotein-CII. J Am Soc Nephrol 28:439–445CrossRefPubMed Nasr SH, Dasari S, Hasadsri L et al (2017) Novel type of renal amyloidosis derived from apolipoprotein-CII. J Am Soc Nephrol 28:439–445CrossRefPubMed
44.
go back to reference Valleix S, Drunat S, Philit J-B et al (2002) Hereditary renal amyloidosis caused by a new variant lysozyme W64R in a French family. Kidney Int 61:907–912CrossRefPubMed Valleix S, Drunat S, Philit J-B et al (2002) Hereditary renal amyloidosis caused by a new variant lysozyme W64R in a French family. Kidney Int 61:907–912CrossRefPubMed
45.
go back to reference Granel B, Valleix S, Serratrice J et al (2006) Lysozyme amyloidosis: report of 4 cases and a review of the literature. Medicine (Baltimore) 85:66–73CrossRef Granel B, Valleix S, Serratrice J et al (2006) Lysozyme amyloidosis: report of 4 cases and a review of the literature. Medicine (Baltimore) 85:66–73CrossRef
46.
go back to reference Nasr SH, Dasari S, Mills JR et al (2017) Hereditary lysozyme amyloidosis variant p.Leu102Ser associates with unique phenotype. J Am Soc Nephrol 28:431–438CrossRefPubMedPubMedCentral Nasr SH, Dasari S, Mills JR et al (2017) Hereditary lysozyme amyloidosis variant p.Leu102Ser associates with unique phenotype. J Am Soc Nephrol 28:431–438CrossRefPubMedPubMedCentral
47.
go back to reference Sethi S, Vrana JA, Theis JD, Dogan A (2013) Mass spectrometry based proteomics in the diagnosis of kidney disease. Curr Opin Nephrol Hypertens 22:273–280CrossRefPubMed Sethi S, Vrana JA, Theis JD, Dogan A (2013) Mass spectrometry based proteomics in the diagnosis of kidney disease. Curr Opin Nephrol Hypertens 22:273–280CrossRefPubMed
48.
go back to reference Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR, Dogan A (2009) Classification of amyloidosis by laser microdissection and mass spectrometry based proteomic analysis in clinical biopsy specimens. Blood 114:4957–4959CrossRefPubMed Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR, Dogan A (2009) Classification of amyloidosis by laser microdissection and mass spectrometry based proteomic analysis in clinical biopsy specimens. Blood 114:4957–4959CrossRefPubMed
49.
go back to reference Dasari S, Theis JD, Vrana JA et al (2014) Clinical proteome informatics workbench detects pathogenic mutations in hereditary amyloidoses. J Proteome Res 13:2352–2358CrossRefPubMed Dasari S, Theis JD, Vrana JA et al (2014) Clinical proteome informatics workbench detects pathogenic mutations in hereditary amyloidoses. J Proteome Res 13:2352–2358CrossRefPubMed
50.
go back to reference Sethi S, Vrana JA, Theis JD et al (2012) Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis. Kidney Int 82:226–234CrossRefPubMedPubMedCentral Sethi S, Vrana JA, Theis JD et al (2012) Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis. Kidney Int 82:226–234CrossRefPubMedPubMedCentral
Metadata
Title
Pathology and diagnosis of renal non-AL amyloidosis
Authors
Sanjeev Sethi
Jason D. Theis
Publication date
01-06-2018
Publisher
Springer International Publishing
Published in
Journal of Nephrology / Issue 3/2018
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-017-0426-6

Other articles of this Issue 3/2018

Journal of Nephrology 3/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.